|
1
|
Saultz JN and Garzon R: Acute myeloid,
leukemia: A concise review. J Clin Med. 5(pii: E33)2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cartwright RA and Staines A: Acute
leukaemias. Baillieres Clin Haematol. 5:1–26. 1992.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dohner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European Leukemia Net. Blood. 115:453–474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dohner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stein EM and Tallman MS: Emerging
therapeutic drugs for AML. Blood. 127:71–78. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Xie Y, Davies SM, Xiang Y, Robison LL and
Ross JA: Trends in leukemia incidence and survival in the United
States (1973-1998). Cancer. 97:2229–2235. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Luke C, Nguyen AM, To B, Seshadri R,
Hughes T, Bardy P, Colbeck M, Buranyi-Trevarton D, McMellon M and
Roder D: Myeloid leukaemia treatment and survival-the South
Australian experience, 1977 to 2002. Asian Pac J Cancer Prev.
7:227–233. 2006.PubMed/NCBI
|
|
8
|
Norsworthy KJ, DeZern AE, Tsai HL, Hand
WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, et
al: Timed sequential therapy for acute myelogenous leukemia:
Results of a retrospective study of 301 patients and review of the
literature. Leuk Res. 61:25–32. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Khaled S, Al-Malki M and Marcucci G: Acute
myeloid leukemia: Biologic, prognostic, and therapeutic insights.
Oncology (Williston Park). 30:318–329. 2016.PubMed/NCBI
|
|
10
|
Tallman MS, Gilliland DG and Rowe JM: Drug
therapy for acute myeloid leukemia. Blood. 106:1154–1163.
2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zeidner JF, Foster MC, Blackford AL,
Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY,
Tibes R, et al: Final results of a randomized multicenter phase II
study of alvocidib, cytarabine and mitoxantrone versus cytarabine
and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid
leukemia (AML). Leuk Res. 72:92–95. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Saini NY, Cerny J, Furtado VF, Desmond A,
Zhou Z, Raffel G, Puthawala I, Bednarik J, Shanahan L, Miron PM, et
al: Elderly do benefit from induction chemotherapy: High dose
mitoxantrone-based (‘5 + 1’) induction chemotherapy regimen in
newly diagnosed acute myeloid leukemia. Am J Hematol. 94:209–215.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pardee TS, Anderson RG, Pladna KM, Isom S,
Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, et al:
A Phase I study of CPI-613 in combination with high-dose cytarabine
and mitoxantrone for relapsed or refractory acute myeloid leukemia.
Clin Cancer Res. 24:2060–2073. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ahmed T, Holwerda S, Klepin HD, Isom S,
Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL and
Pardee TS: High dose cytarabine, mitoxantrone and l-asparaginase
(HAMA) salvage for relapsed or refractory acute myeloid leukemia
(AML) in the elderly. Leuk Res. 39:945–949. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jia LT, Chen SY and Yang AG: Cancer gene
therapy targeting cellular apoptosis machinery. Cancer Treat Rev.
38:868–876. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dübbers A, Würthwein G, Müller HJ,
Schulze-Westhoff P, Winkelhorst M, Kurzknabe E, Lanvers C, Pieters
R, Kaspers GJ, Creutzig U, et al: Asparagine synthetase activity in
paediatric acute leukaemias: AML-M5 subtype shows lowest activity.
Br J Haematol. 109:427–429. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Baud V and Karin M: Signal transduction by
tumor necrosis factor and its relatives. Trends Cell Biol.
11:372–377. 2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shen HM and Pervaiz S: TNF receptor
superfamily-induced cell death: Redox-dependent execution. FASEB J.
20:1589–1598. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Galluzzi L, Pietrocola F, Bravo-San Pedro
JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J,
Gewirtz DA, Karantza V, et al: Autophagy in malignant
transformation and cancer progression. EMBO J. 34:856–880.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Puissant A, Robert G and Auberger P:
Targeting autophagy to fight hematopoietic malignancies. Cell
Cycle. 9:3470–3478. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lin L and Baehrecke EH: Autophagy, cell
death, and cancer. Mol Cell Oncol. 2(e985913)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tanida I, Sou YS, Minematsu-Ikeguchi N,
Ueno T and Kominami E: Atg8L/Apg8L is the fourth mammalian modifier
of mammalian Atg8 conjugation mediated by human Atg4B, Atg7 and
Atg3. FEBS J. 273:2553–2562. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mann SS and Hammarback JA: Molecular
characterization of light chain 3. A microtubule binding subunit of
MAP1A and MAP1B. J Biol Chem. 269:11492–11497. 1994.PubMed/NCBI
|
|
24
|
Wu J, Dang Y, Su W, Liu C, Ma H, Shan Y,
Pei Y, Wan B, Guo J and Yu L: Molecular cloning and
characterization of rat LC3A and LC3B-two novel markers of
autophagosome. Biochem Biophys Res Commun. 339:437–442.
2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shpilka T, Weidberg H, Pietrokovski S and
Elazar Z: Atg8: An autophagy-related ubiquitin-like protein family.
Genome Biol. 12(226)2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
He H, Dang Y, Dai F, Guo Z, Wu J, She X,
Pei Y, Chen Y, Ling W, Wu C, et al: Post-translational
modifications of three members of the human MAP1LC3 family and
detection of a novel type of modification for MAP1LC3B. J Biol
Chem. 278:29278–29287. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sou YS, Tanida I, Komatsu M, Ueno T and
Kominami E: Phosphatidylserine in addition to
phosphatidylethanolamine is an in vitro target of the mammalian
Atg8 modifiers, LC3, GABARAP, and GATE-16. J Biol Chem.
281:3017–3024. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Taguchi-Atarashi N, Hamasaki M, Matsunaga
K, Omori H, Ktistakis NT, Yoshimori T and Noda T: Modulation of
local PtdIns3P levels by the PI phosphatase MTMR3 regulates
constitutive autophagy. Traffic. 11:468–478. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tanida I: Autophagy basics. Microbiol
Immunol. 55:1–11. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Song P, Ye L, Fan J, Li Y, Zeng X, Wang Z,
Wang S, Zhang G, Yang P, Cao Z and Ju D: Asparaginase induces
apoptosis and cytoprotective autophagy in chronic myeloid leukemia
cells. Oncotarget. 6:3861–3873. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yoshii SR and Mizushima N: Monitoring and
measuring autophagy. Int J Mol Sci. 18(pii: E1865)2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gollner S, Oellerich T, Agrawal-Singh S,
Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S,
et al: Loss of the histone methyltransferase EZH2 induces
resistance to multiple drugs in acute myeloid leukemia. Nat Med.
23:69–78. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Hourigan CS, Gale RP, Gormley NJ,
Ossenkoppele GJ and Walter RB: Measurable residual disease testing
in acute myeloid leukaemia. Leukemia. 31:1482–1490. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Xu B, Zhao Y, Wang X, Gong P and Ge W:
MZH29 is a novel potent inhibitor that overcomes drug resistance
FLT3 mutations in acute myeloid leukemia. Leukemia. 31:913–921.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pollyea DA and Jordan CT: Therapeutic
targeting of acute myeloid leukemia stem cells. Blood.
129:1627–1635. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Estey EH: Treatment of acute myeloid
leukemia. Haematologica. 94:10–16. 2009.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Subramanian S and Kartha RV:
MicroRNA-mediated gene regulations in human sarcomas. Cell Mol Life
Sci. 69:3571–3585. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kabat AM, Pott J and Maloy KJ: The mucosal
immune system and its regulation by autophagy. Front Immunol.
7(240)2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ndoye A and Weeraratna AT: Autophagy-An
emerging target for melanoma therapy. F1000Res. 5(pii:
F1000)2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Li CJ, Liao WT, Wu MY and Chu PY: New
insights into the role of autophagy in tumor immune
microenvironment. Int J Mol Sci. 18(pii: E1566)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhang WX, Zhou JC, Peng D, Hua F, Li K, Yu
JJ, Lv XX, Cui B, Liu SS, Yu JM, et al: Disrupting the TRIB3-SQSTM1
interaction reduces liver fibrosis by restoring autophagy and
suppressing exosome-mediated HSC activation. Autophagy. 1–15.
2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Karvela M, Baquero P, Kuntz EM,
Mukhopadhyay A, Mitchell R, Allan EK, Chan E, Kranc KR, Calabretta
B, Salomoni P, et al: ATG7 regulates energy metabolism,
differentiation and survival of Philadelphia-chromosome-positive
cells. Autophagy. 12:936–948. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Rothe K, Lin H, Lin KB, Leung A, Wang HM,
Malekesmaeili M, Brinkman RR, Forrest DL, Gorski SM and Jiang X:
The core autophagy protein ATG4B is a potential biomarker and
therapeutic target in CML stem/progenitor cells. Blood.
123:3622–3634. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Yu Y, Zhang X, Tian H, Zhang Z and Tian Y:
Knockdown of long non-coding RNA HOTAIR increases cisplatin
sensitivity in ovarian cancer by inhibiting cisplatin-induced
autophagy. J BUON. 23:1396–1401. 2018.PubMed/NCBI
|
|
45
|
Song X, Liu L, Chang M, Geng X, Wang X,
Wang W, Chen TC, Xie L and Song X: NEO212 induces mitochondrial
apoptosis and impairs autophagy flux in ovarian cancer. J Exp Clin
Cancer. 38(239)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gong C, Bauvy C, Tonelli G, Yue W,
Deloménie C, Nicolas V, Zhu Y, Domergue V, Marin-Esteban V,
Tharinger H, et al: Beclin 1 and autophagy are required for the
tumorigenicity of breast cancer stem-like/progenitor cells.
Oncogene. 322261–2672. (2272e.1-11)2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mitter SK, Song C, Qi X, Mao H, Rao H,
Akin D, Lewin A, Grant M, Dunn W Jr, Ding J, et al: Dysregulated
autophagy in the RPE is associated with increased susceptibility to
oxidative stress and AMD. Autophagy. 10:1989–2005. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lu Z, Chen C, Wu Z, Miao Y, Muhammad I,
Ding L, Tian E, Hu W, Ni H, Li R, et al: A dual role of P53 in
regulating colistin-induced autophagy in PC-12 cells. Front
Pharmacol. 8(768)2017.PubMed/NCBI View Article : Google Scholar
|
